Targeting systemic inflammation in metabolic disorders. A therapeutic candidate for the prevention of cardiovascular diseases?

Cardiovascular disease (CVD) remains the leading cause of death and disability worldwide. While many factors can contribute to CVD, atherosclerosis is the cardinal underlying pathology, and its development is associated with several metabolic risk factors including dyslipidemia and obesity. Recent s...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacological research 2024-02, Vol.200, p.107058-107058, Article 107058
Main Authors: Domingo, Elena, Marques, Patrice, Francisco, Vera, Piqueras, Laura, Sanz, Maria-Jesus
Format: Article
Language:English
Subjects:
Anti-inflammatory effects
Anti-obesity drugs
Atherosclerosis - complications
Atherosclerosis - drug therapy
Atherosclerosis - prevention & control
Cardiovascular Diseases - drug therapy
Cardiovascular Diseases - etiology
Cardiovascular Diseases - prevention & control
Endothelial dysfunction
Humans
Hypercholesterolemia
Hypercholesterolemia - complications
Hyperlipidemias
Inflammation - complications
Lipid-lowering therapies
Obesity
Obesity - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cardiovascular disease (CVD) remains the leading cause of death and disability worldwide. While many factors can contribute to CVD, atherosclerosis is the cardinal underlying pathology, and its development is associated with several metabolic risk factors including dyslipidemia and obesity. Recent studies have definitively demonstrated a link between low-grade systemic inflammation and two relevant metabolic abnormalities: hypercholesterolemia and obesity. Interestingly, both metabolic disorders are also associated with endothelial dysfunction/activation, a proinflammatory and prothrombotic phenotype of the endothelium that involves leukocyte infiltration into the arterial wall, one of the earliest stages of atherogenesis. This article reviews the current literature on the intricate relationship between hypercholesterolemia and obesity and the associated systemic inflammation and endothelial dysfunction, and discusses the effectiveness of present, emerging and in-development pharmacological therapies used to treat these metabolic disorders with a focus on their effects on the associated systemic inflammatory state and cardiovascular risk. [Display omitted]
ISSN:1043-6618
1096-1186
DOI:10.1016/j.phrs.2024.107058